Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02807675 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)
A Phase 1 study of Parkinson's Disease, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 11
- Study locations
NCT02807675 is a Phase 1 study of Parkinson's Disease that has completed, run by Acorda Therapeutics. The registered enrollment target is 36 participants, below the 639-participant average among 157 other Parkinson's Disease trials with a reported enrollment target (94% lower). The trial reports 11 study locations across 6 states.
The verdict
NCT02807675, a Phase 1 study of Parkinson's Disease, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study is a double-blind, randomized, placebo-controlled, 2-way crossover study to evaluate the safety of CVT-301 levodopa (l-dopa) when co- administered with the first daily dose of oral levodopa/carbidopa for early morning OFF symptoms in patients with Parkinson's disease (PD).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG CVT-301, LIP
Study Locations (11)
Florida
- Site #9002 - Boca Raton
- Site #9017 - Hallandale
- Site #9008 - St. Petersburg
- Site #9018 - Sunrise
- Site #9004 - Tampa
Michigan
- Site #9003 - Farmington Hills
- Site #9005 - West Bloomfield
California
- Site #9015 - Fountain Valley
Georgia
- Site #9016 - Atlanta
Illinois
- Site #9009 - Chicago
Tennessee
- Site #9007 - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-06 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02807675
The ClinicalTrials.gov registry entry for NCT02807675 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 639-participant average among 157 other Parkinson's Disease trials with a reported enrollment target (94% lower). The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02807675 reports 11 study locations spanning 6 distinct geographic areas - top geographies include Florida, Michigan, California.
Frequently Asked Questions
What is clinical trial NCT02807675 about?
NCT02807675 is a clinical study titled "A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)". This study is a double-blind, randomized, placebo-controlled, 2-way crossover study to evaluate the safety of CVT-301 levodopa (l-dopa) when co- administered with the first daily dose of oral levodopa/carbidopa for early morning OFF symptoms in patients with Parkinson's disease (PD).
What is the current status of trial NCT02807675?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2016-06. Estimated completion is 2016-11.
What conditions does trial NCT02807675 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT02807675?
The interventions under investigation include: Placebo (OTHER), CVT-301, LIP (DRUG).
Who is sponsoring clinical trial NCT02807675?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02807675 being conducted?
This trial has 11 study locations across California, Florida, Georgia, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
RECRUITING · Phase 1
-
A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery
RECRUITING · Phase 1
-
A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
RECRUITING · Phase 1
-
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.